|
More
Venture Capital
Research Library
|
|
Life Science Leader
|
An exclusive interview with Steven Burrill By Cliff Mintz
G. Steven Burrill has devoted his entire career to helping life sciences compa- nies start up operations and sustain their growth. In 1994, he started Burrill & Company — a venture capital (VC), private equity, merchant banking, and media life sciences firm. The Burrill family of life sciences venture capital funds now manages more than ...
|
|
|
Life Science Leader
|
Soon after the financial meltdown began late last fall, J. Leslie Glick, Ph.D. (see sidebar on profile of Dr. Glick), who is a staunch supporter of capitalization and free enterprise, proposed the government provide stimulus monies to VC firms to ensure the continued growth and financial stability of the U.S. life sciences industry. In exchange for taxpayer investment in these firms, the federal ...
|
|
|
Beremans Ltd
|
Beremans Limited provides investment research services for the Life Sciences sector, primarily for fund managers and venture capital organisations. Core activities are summarised below.
• Due Diligence – a rigorous examination of the key areas pertinent to the success of a given Life Sciences company, such as competition, technology, products, markets and financial projections, and provision of ...
|
|
|
Quintiles Transnational
|
In the face of clear evidence that “business as usual” is no longer an option for the biopharmaceutical sector, companies are exhibiting an unprecedented willingness to share experiences and ideas for solutions to industry-wide problems.
Some key questions surfacing in the dialogue include: Are productivity, cost and timeline trends continuing? Are they universal? Is the old business model ...
|
|
|
GVK Biosciences Private Limited
|
Recent industry analyst reports predict that worldwide pharmaceutical industry revenues will grow at a compound annual growth rate (CAGR) of 8.58% through 2008. Worldwide biotechnology revenues are expected to grow at a compound annual growth rate of 25.96% through 2008 – this large growth rate is not surprising as many biotechnology and biopharmaceutical companies are just now moving products ...
|
|
|
|
